The peptide activates the FAK-paxillin pathway essential for cell migration, while influencing EGR-1 and growth hormone receptor expression
It also positively influences the expression of various genes, many of which are associated with healing, immune responses, and overall cellular health
Its pivotal trial enrolled 816 participants and met its primary efficacy endpoint, supporting FDA approval in 2010 with documented visceral fat reductions of roughly 15-18% over 26 weeks
Factors such as the form of B12 used, additional ingredients, and manufacturing standards should be considered
This synergistic blend enhances the body's natural healing processes by improving blood flow, reducing inflammation, and accelerating repair of muscles, tendons, ligaments, and joints